Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers.
ERBB2
HER2
circulating tumor DNA
copy number gain
next-generation sequencing
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
11
2021
accepted:
10
01
2022
entrez:
7
2
2022
pubmed:
8
2
2022
medline:
8
2
2022
Statut:
epublish
Résumé
The correlation of ERBB2 copy number gain (CNG) from tissue or circulating tumor DNA (ctDNA) by next-generation sequencing (NGS) with standard HER2 tissue evaluation is not well understood. We retrospectively identified patients with ERBB2 CNG on commercial NGS. We described their clinical-pathologic features and calculated the positive predictive value (PPV) of ERBB2 CNG by NGS for HER2-positivity by IHC and FISH testing. 176 patients had NGS revealing an ERBB2 CNG (112 by tumor tissue and 91 by ctDNA). The cancer subtypes with the most cases with ERBB2 CNG by NGS were breast ( ERBB2 CNG by NGS is detected in numerous malignancies for which HER2 testing is not standard. Detection of ERBB2 CNG by tissue NGS and ctDNA has a high PPV for true HER2-positivity by standard IHC and/or FISH testing in breast cancer.
Sections du résumé
BACKGROUND
The correlation of ERBB2 copy number gain (CNG) from tissue or circulating tumor DNA (ctDNA) by next-generation sequencing (NGS) with standard HER2 tissue evaluation is not well understood.
MATERIALS AND METHODS
We retrospectively identified patients with ERBB2 CNG on commercial NGS. We described their clinical-pathologic features and calculated the positive predictive value (PPV) of ERBB2 CNG by NGS for HER2-positivity by IHC and FISH testing.
RESULTS
176 patients had NGS revealing an ERBB2 CNG (112 by tumor tissue and 91 by ctDNA). The cancer subtypes with the most cases with ERBB2 CNG by NGS were breast (
CONCLUSIONS
ERBB2 CNG by NGS is detected in numerous malignancies for which HER2 testing is not standard. Detection of ERBB2 CNG by tissue NGS and ctDNA has a high PPV for true HER2-positivity by standard IHC and/or FISH testing in breast cancer.
Identifiants
pubmed: 35126865
doi: 10.18632/oncotarget.28188
pii: 28188
pmc: PMC8809397
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
273-280Informations de copyright
Copyright: © 2022 Shah et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST ANS reports honorarium from AstraZeneca. AB reports speaker fees from Lilly, Roche, Thermo fisher scientific, and Foundation Medicine.
Références
Am J Clin Pathol. 2019 Jun 5;152(1):97-108
pubmed: 31115453
Breast. 2020 Feb;49:261-266
pubmed: 31927339
Nature. 2017 Aug 17;548(7667):297-303
pubmed: 28783718
Ann Oncol. 2019 Nov 1;30(11):1821-1830
pubmed: 31504139
Lancet Oncol. 2021 Sep;22(9):1290-1300
pubmed: 34339623
Cancer Sci. 2017 Sep;108(9):1881-1887
pubmed: 28677165
Clin Cancer Res. 2019 Jan 1;25(1):64-72
pubmed: 30206164
J Mol Diagn. 2017 Mar;19(2):244-254
pubmed: 28027945
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
JCO Oncol Pract. 2021 Nov;17(11):e1774-e1784
pubmed: 34043456
Pathol Oncol Res. 2020 Oct;26(4):2577-2585
pubmed: 32621174
Lung Cancer. 2014 Sep;85(3):373-8
pubmed: 25047676
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Mod Pathol. 2007 May;20(5):584-91
pubmed: 17396141
Eur J Cancer. 2018 Jan;88:92-100
pubmed: 29207318
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
J Clin Oncol. 2017 Feb;35(4):446-464
pubmed: 28129524
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Cancer Discov. 2018 Jan;8(1):37-48
pubmed: 28978556
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Lancet Oncol. 2019 Apr;20(4):518-530
pubmed: 30857956
JCO Precis Oncol. 2020 Nov;4:6-19
pubmed: 35050726